Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GMAB 
Genmab AS (GMAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: GMAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $37.54
1 Year Target Price $37.54
| 4 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.1% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 20.48B USD | Price to earnings Ratio 16.97 | 1Y Target Price 37.54 |
Price to earnings Ratio 16.97 | 1Y Target Price 37.54 | ||
Volume (30-day avg) 9 | Beta 0.82 | 52 Weeks Range 17.23 - 33.65 | Updated Date 10/16/2025 |
52 Weeks Range 17.23 - 33.65 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.93 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 37.59% | Operating Margin (TTM) 38.92% |
Management Effectiveness
Return on Assets (TTM) 13.26% | Return on Equity (TTM) 28.12% |
Valuation
Trailing PE 16.97 | Forward PE 14.56 | Enterprise Value 16837903311 | Price to Sales(TTM) 5.62 |
Enterprise Value 16837903311 | Price to Sales(TTM) 5.62 | ||
Enterprise Value to Revenue 5.16 | Enterprise Value to EBITDA 11.41 | Shares Outstanding 615546220 | Shares Floating 60786023 |
Shares Outstanding 615546220 | Shares Floating 60786023 | ||
Percent Insiders - | Percent Institutions 10.44 |
Upturn AI SWOT
Genmab AS
Company Overview
History and Background
Genmab AS is a biotechnology company founded in 1999 in Copenhagen, Denmark. It focuses on creating and developing differentiated antibody therapeutics for the treatment of cancer and other diseases. Initially focused on collaborative research, it has evolved into a fully integrated biotechnology company with its own proprietary products and clinical programs.
Core Business Areas
- Oncology Antibody Therapeutics: Focuses on developing and commercializing antibody-based therapies for various cancer types. This is Genmab's core business and driver of revenue.
- Technology Platform: Genmab has developed several proprietary antibody technology platforms, including DuoBodyu00ae and HexaBodyu00ae, which are used to generate novel antibody therapeutics.
- Partnerships and Licensing: Genmab collaborates with other pharmaceutical and biotechnology companies to develop and commercialize its antibody therapeutics.
Leadership and Structure
Genmab is led by Jan van de Winkel, Ph.D., Chief Executive Officer. The company has a board of directors and an executive management team responsible for overseeing its strategic direction and operations. The organizational structure is based on functional departments (e.g., R&D, Commercial, Finance).
Top Products and Market Share
Key Offerings
- Darzalex (daratumumab): A CD38-directed antibody approved for multiple myeloma. Co-developed and commercialized with Janssen Biotech (Johnson & Johnson). Darzalex is a leading treatment for multiple myeloma. Competitors: Sarclisa (isatuximab-irfc) from Sanofi, Empliciti (elotuzumab) from Bristol Myers Squibb.
- Kesimpta (ofatumumab): A CD20-directed antibody approved for relapsing forms of multiple sclerosis. Originally developed by Genmab and licensed to Novartis. Competitors: Ocrevus (ocrelizumab) from Roche, Briumvi (ublituximab-xiiy) from TG Therapeutics.
- Tivdak (tisotumab vedotin-tftv): An antibody-drug conjugate (ADC) approved for recurrent or metastatic cervical cancer. Co-developed and commercialized with Seagen (now part of Pfizer). Competitors: Chemotherapy.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. The oncology market is particularly competitive with increasing demand for targeted therapies. There is a high demand for the development of new monoclonal antibody products.
Positioning
Genmab is a leader in antibody therapeutics, with strong expertise in antibody engineering and development. It is positioned as an innovator with a focus on developing differentiated products. Its competitive advantage lies in its proprietary technology platforms and strategic partnerships. Genmab uses their HuMaxu00ae platform for developing antibody-based pharmaceuticals. Their most successful platform is DuoBodyu00ae.
Total Addressable Market (TAM)
The global monoclonal antibodies market is expected to reach approximately $300 billion by 2030. Genmab is positioned to capture a significant share of this market with its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary antibody technology platforms (DuoBodyu00ae, HexaBodyu00ae)
- Successful collaborations with leading pharmaceutical companies
- Strong pipeline of antibody therapeutics in development
- Approved products generating significant revenue
- Expertise in antibody engineering and development
Weaknesses
- Reliance on partnerships for commercialization of some products
- High R&D costs and development timelines
- Dependence on key products like Darzalex and Kesimpta
- Vulnerability to clinical trial failures
Opportunities
- Expansion of existing product indications
- Development of new antibody therapeutics for unmet medical needs
- Strategic acquisitions to expand product portfolio
- Leveraging technology platforms for new collaborations
- Emerging markets expansion
Threats
- Competition from other biotechnology and pharmaceutical companies
- Patent expirations and biosimilar competition
- Regulatory hurdles and changes in reimbursement policies
- Clinical trial failures
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- SNY
- BMY
- NVS
- PFE
- RHHBY
Competitive Landscape
Genmab competes with other biotechnology and pharmaceutical companies in the development and commercialization of antibody therapeutics. Genmabu2019s strengths lie in its innovative technology platforms and strong partnerships. Weaknesses include reliance on a few key products and the risk of clinical trial failures.
Major Acquisitions
ProFoundBio
- Year: 2024
- Acquisition Price (USD millions): 182
- Strategic Rationale: Acquisition of ProFoundBio provides Genmab with innovative oncology drug targets for ADC applications.
Growth Trajectory and Initiatives
Historical Growth: Genmab has experienced significant growth in revenue and profitability over the past 5 years, driven by the success of its key products. The company has also expanded its pipeline and strengthened its technology platforms.
Future Projections: Analysts project continued revenue growth for Genmab, driven by increasing sales of Darzalex and Kesimpta, as well as the potential launch of new products. The company's pipeline and partnerships provide a solid foundation for future growth.
Recent Initiatives: Recent initiatives include expanding the indications for Darzalex, advancing clinical trials for new antibody therapeutics, and strengthening strategic partnerships. Genmab is expanding its manufacturing capabilities to support future growth.
Summary
Genmab is a strong biotechnology company with leading positions in antibody therapeutics. Its success is driven by effective partnerships and novel technologies. Weaknesses include its dependency on several key drugs, and the market is highly competitive. Genmab has experienced tremendous growth in revenue and profitability as the company grows.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Genmab AS Annual Reports
- Company Website
- Analyst Reports
- SEC Filings
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market conditions and company performance are subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genmab AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2009-06-01 | Co-Founder, President & CEO Dr. Jan G.J. van de Winkel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2639 | Website https://www.genmab.com |
Full time employees 2639 | Website https://www.genmab.com | ||
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.